Tobira Therapeutics has received a new patent from the US Patent and Trademark Office that covers the use of TBR-652, a CCR5 antagonist currently in Phase I development for the treatment of HIV-1 infection in adults.

This patent is part of Tobira's portfolio of medicines to treat infectious diseases. In addition, the company recently received a European patent for TBR-220, a second CCR5 antagonist for the treatment of HIV/AIDS.

James Sapirstein, CEO of Tobira Therapeutics, said: "It is gratifying to progress the intellectual property of these compounds and look forward to future clinical trial results."